 |
|
|
|
|
|
 |
|
|
|
| |
|
|
 |
| |
 |
| |
| Research subjects are the individuals
who participate in a research project. At
CRU, we strive to provide the best care
possible to our study participants. They
have frequent one-on-one contact with the
research nurses. In addition to coordinating
their study-related care, the nurses
frequently serve as a liaison between the
study doctor and the primary care physician.
If the patient chooses, most study-related
procedures and results can be forwarded to
the primary care physician to avoid having
duplicate tests completed. |
| |
Research patients can reach nurses at
either location:
Ohio University
Heritage
College of Osteopathic Medicine
018 Parks Hall
Athens, OH 45701
740-593-2410 (phone)
740-597-1447 (fax)
Ohio University
Heritage
College of Osteopathic Medicine
Castrop Center
75 Hospital Dr.
Suite 200
Athens, OH 45701
740-566-4873 (phone)
740-566-4874 (fax)
877-762-3888 (toll-free)
If the patient experiences a
research-related emergency after hours, he
or she may contact the answering service at
740-594-2416 to page someone on the research
team. |
| |
| |
|
Corporate-Sponsored Studies: |
| |
1. Type 2 Diabetes Study, Dr. Frank
Schwartz, Primary Investigator
BCB106 study: A randomized, double-blind,
parallel-group multi-center study to compare
the glycemic effect, safety, and
tolerability of study drug to those of
sitagliptin and pioglitazone (Actos) in
subjects with type 2 diabetes treated with
metformin only. 12 visits with 2 phone calls
(26 week). |
| |
2. Diabetes Prevention Study, Dr. Frank
Schwartz, Primary Investigator
TrialNet: The goal of the TrialNet study
of the Development of Type 1 Diabetes are to
gain information about the natural history
and pathogeneses of type 1 diabetes and to
facilitate the recruitment and assessment of
individuals who might quality for type 1
diabetes prevention trials. |
| |
3. Type 2 Diabetes Study, Dr. Jay Shubrook, Primary Investigator
Emerge 3: A multi-center, randomized,
double-blind, placebo-controlled study to
asses the efficacy, safety, and tolerability
of study drug compared to placebo in
patients with type 2 diabetes mellitus
inadequately controlled with metformin plus
pioglitazone. |
| |
4. Type 2 Diabetes Study, Dr. Jay Shubrook, Primary Investigator
GetGoal-L: A randomized, open-label,
active-controlled, 2-arm parallel-group,
multi-center study with a 24-week main
treatment period and an extension assessing
the efficacy and safety of study drug in
patients with type 2 diabetes insufficiently
controlled with basal insulin. (Lantus +/-
metformin). |
| |
5. Type 2 Diabetes Study, Dr. Jay Shubrook, Primary Investigator
GetGoal-P : A randomized, open-label,
active-controlled, 2-arm parallel-group,
multi-center study with a 24-week main
treatment period and an extension assessing
the efficacy and safety of study drug in
patients with type 2 diabetes insufficiently
controlled with Actos (+/- metformin). |
| |
|
6. Type 2 Diabetes Study, Dr. Jay Shubrook,
Primary Investigator
GetGoal-Mono: A randomized,
double-blind, placebo-controlled,
parallel-group, multicenter 12-week study
assessing the efficacy and safety of study
drug in patients with type 2 diabetes not
treated with antidiabetic agents. |
| |
|
Investigator-Initiated Studies: |
| |
| 1. “Creation of an Ohio University
Diabetes/Endocrine Diseases Patient Database
and Biorepository.” Frank Schwartz, M.D.,
Principal Investigator, (Currently
enrolling patients) |
| |
| 2. “Use of Continuous Glucose Monitoring
(CGMS) to Transition Patients with Type 1
Diabetes from Multiple Daily Injections
(MDI) of Insulin to the Insulin Pump.” Frank
Schwartz, M.D., Principal Investigator.
(Currently enrolling patients) |
| |
| 3. “Design and Effects of
Physiologically Based Hormone Therapy in
Perimenopausal Women”. Andrea S. Clem, DO,
and Felicia V. Nowak, MD, PhD, Principal
Investigators, Suzanne E. Hatty, PhD,
Co-investigator. (Currently enrolling
patients) |
| |
| 4. “Intelligent Decision Support for
Type 1 Diabetics on Insulin Therapy.” Frank
Schwartz, M.D., Principal Investigator
(Enrollment open) |
| |
| 5. Frank Schwartz, M.D./David Theis-
Suppression/Replacement Therapy in Grave's
Disease (Enrollment open) |
| |
| 6. Jay Shubrook D.O./Rachel Holt D.O./Tracy
Marx, D.O.- Diabetes Management in Extended
Care Facilities (Enrollment open) |
| |
| 7. "Mechanisms of Immune Modulation by
Osteopathic Manipulative Therapy-Induced
Nitric Oxide." Kenneth Goodrum, Ph.D.,
Principal Investigator |
|
| |
|
|
|
| |
|
|
|
|
|
| |
Ohio University
Heritage
College of Osteopathic Medicine
Grosvenor Hall, Athens, Ohio 45701
Tel: 740-593-2410 |
|
|
|
|
